Key Points
- Mirum Pharmaceuticals CFO Eric Bjerkholt sold 6,001 shares at an average price of $99.90, totaling approximately $599,500. The transaction, conducted under a Rule 10b5-1 plan, reduced his holdings by 14.17% to 36,355 shares.
- Mirum reported quarterly revenue of $176.24 million, up 37.9% year over year and above estimates, but its adjusted loss of $1.06 per share missed expectations of $0.74.
- Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $137.33, compared with the stock’s reported opening price of $98.97.
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) CFO Eric Bjerkholt sold 6,001 shares of the firm's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $99.90, for a total value of $599,499.90. Following the completion of the transaction, the chief financial officer owned 36,355 shares in the company, valued at approximately $3,631,864.50. This trade represents a 14.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Eric Bjerkholt also recently made the following trade(s):
- On Monday, July 6th, Eric Bjerkholt sold 5,000 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $122.25, for a total value of $611,250.00.
- On Monday, June 8th, Eric Bjerkholt sold 5,000 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $93.82, for a total value of $469,100.00.
Mirum Pharmaceuticals Stock Up 0.8%
MIRM stock opened at $98.97 on Thursday. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $63.23 and a fifty-two week high of $130.00. The business's 50-day moving average is $110.64 and its two-hundred day moving average is $101.97. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.74 and a current ratio of 2.86. The company has a market cap of $6.43 billion, a price-to-earnings ratio of -6.80 and a beta of 0.52.
Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.32). The firm had revenue of $176.24 million for the quarter, compared to the consensus estimate of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The company's revenue for the quarter was up 37.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.12) earnings per share. As a group, analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.31 earnings per share for the current year.
Analysts Set New Price Targets
MIRM has been the subject of several recent research reports. Morgan Stanley set a $137.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, August 6th. Raymond James Financial reissued a "strong-buy" rating and set a $165.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Royal Bank Of Canada reduced their price objective on Mirum Pharmaceuticals from $148.00 to $135.00 and set an "outperform" rating for the company in a research note on Thursday, August 6th. Citigroup restated an "outperform" rating on shares of Mirum Pharmaceuticals in a research note on Thursday, August 6th. Finally, TD Cowen decreased their target price on Mirum Pharmaceuticals from $145.00 to $140.00 and set a "buy" rating on the stock in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $137.33.
View Our Latest Research Report on Mirum Pharmaceuticals
Institutional Investors Weigh In On Mirum Pharmaceuticals
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cullen Frost Bankers Inc. bought a new stake in Mirum Pharmaceuticals during the 4th quarter worth approximately $30,000. Eurizon Capital SGR S.p.A. bought a new position in shares of Mirum Pharmaceuticals in the fourth quarter worth approximately $32,000. CIBC Private Wealth Group LLC bought a new position in shares of Mirum Pharmaceuticals in the fourth quarter worth approximately $32,000. Quantbot Technologies LP purchased a new stake in shares of Mirum Pharmaceuticals in the third quarter worth $33,000. Finally, Comerica Bank increased its stake in shares of Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company's stock worth $40,000 after purchasing an additional 278 shares in the last quarter.
Mirum Pharmaceuticals Company Profile
(
Get Free Report)
Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.
Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
